Federated Hermes, Inc. Beyond Spring Inc. Transaction History

Federated Hermes, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.56 - $2.61 $530 - $2,471	-947 Reduced 24.03%	2,994 $5,000
Q3 2022 Nov 14, 2022	BUY	$0.97 - $1.81 $66 - $124	69 Added 1.78%	3,941 $4,000
Q2 2022 Aug 15, 2022	BUY	$1.13 - $2.66 $2,448 - $5,764	2,167 Added 127.1%	3,872 $6,000
Q1 2022 May 13, 2022	BUY	$1.68 - $5.01 $2,864 - $8,542	1,705 New	1,705 $4,000
Q2 2021 Aug 16, 2021	SELL	$9.37 - $12.12 $112,336 - $145,306	-11,989 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$10.61 - $15.77 $68,795 - $102,252	6,484 Added 117.78%	11,989 $133,000
Q4 2020 Feb 12, 2021	BUY	$10.21 - $17.31 $56,206 - $95,291	5,505 New	5,505 $67,000
Q2 2020 Aug 13, 2020	SELL	$11.21 - $18.15 $41,409 - $67,046	-3,694 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$9.68 - $18.47 $8,595 - $16,401	-888 Reduced 19.38%	3,694 $47,000
Q4 2019 Feb 14, 2020	BUY	$11.83 - $18.68 $53,329 - $84,209	4,508 Added 6091.89%	4,582 $71,000
Q3 2019 Nov 14, 2019	BUY	$15.33 - $23.85 $1,134 - $1,764	74 New	74 $1,000

5.77M

53.2K

2.5K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $91.5M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.